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ABSTRACT
Celyvir (autologous mesenchymal cells -MSCs- that carry an oncolytic adenovirus) 
is a new therapeutic strategy for metastatic tumors developed by our research 
group over the last decade. There are limitations for studying the immune effects of 
human oncolytic adenoviruses in murine models since these viruses do not replicate 
naturally in these animals. The use of xenografts in immunodeficient mice prevent 
assessing important clinical aspects of this therapy such as the antiadenoviral immune 
response or the possible intratumoral immune changes, both of tumor infiltrating 
leukocytes and of the microenvironment. In our strategy, the presence of MSCs in the 
medicinal product adds an extra level of complexity. We present here a murine model 
that overcomes many of these limitations. We found that carrier cells outcompeted 
intravenous administration of naked particles in delivering the oncolytic virus into the 
tumor masses. The protection that MSCs could provide to the oncolytic adenovirus did 
not preclude the development of an antiadenoviral immune response. However, the 
presence of circulating antiadenoviral antibodies did not prevent changes detected at 
the tumor masses: increased infiltration and changes in the quality of immune cells 
per unit of tumor volume, and a less protumoral and more inflammatory profile of the 
tumor microenvironment. We believe that the model described here will enable the 
study of crucial events related to the immune responses affecting both the medicinal 
product and the tumor.
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INTRODUCTION
Celyvir (autologous mesenchymal cells -MSCs- 
that carry an oncolytic adenovirus [1] inside) is a new 
therapeutic strategy for metastatic tumors developed 
by our research group over the last decade. The first 
clinical trial with Celyvir [2] for children and adults with 
metastatic and refractory solid tumors (ClinicalTrials 
Identifier: NCT01844661; EudraCT2008-000364-16) 
and a compassionate use program [3] have shown that 
Celyvir is a very well tolerated treatment, with only mild 
toxicities related to the adenoviral infusion (fever, chills 
and discomfort) with the potential to achieve clinical 
responses in patients with advanced tumors.
Nowadays it is assumed that oncolytic virotherapy 
can be considered as a form of cancer immunotherapy [4], 
since the reported clinical benefits have been associated 
with antitumor immune phenomena initiated by infection 
and oncolysis. Results of preclinical models and human 
trials demonstrate that the localized effect of oncolytic 
viruses is capable of activating an inflammatory immune 
infiltrate in tumors. This point is of vital importance, since 
it is known that tumor infiltration by T lymphocytes is 
a prerequisite for the success of immunotherapies based 
on inhibitors of immune checkpoints [5]. Oncolytic 
virotherapy, and therefore Celyvir, appears as a strategy 
capable of achieving tumor infiltration by lymphocytes 
in any type of tumor, in principle. In addition to its 
action on tumor infiltrating leukocytes, oncolytic 
virotherapies can also act on the tolerant state of the tumor 
microenvironment [6].
There are limitations for studying the immune 
effects of human oncolytic adenoviruses in animal models 
since these viruses do not replicate naturally in murine 
models. The use of xenografts in immunodeficient mice 
allows the analysis of aspects related to oncolysis or 
tumor targeting but no other important clinical facets such 
as the antiadenoviral immune response or the possible 
intratumoral immune changes, both of tumor infiltrating 
leukocytes and of the microenvironment. In addition to 
the importance of the various immune reactions associated 
with oncolytic virotherapy, our strategy incorporates the 
well-known immunomodulatory role of mesenchymal 
stem cells (MSCs) [7–14]. We have explored the possibility 
of an immunocompetent murine model of neuroblastoma, 
a childhood tumor treated with Celyvir by our group. In 
this model, we comprehensively analyzed biodistribution 
of Celyvir, adenoviral levels in peripheral blood, 
antiadenoviral response and intratumor immune changes 
associated with repeated administrations of an oncolytic 
adenovirus carried by MSCs. We found that carrier cells 
outcompeted intravenously (IV) administration of naked 
particles in delivering the oncolytic virus into the tumor 
masses. The protection that MSCs could provide to the 
oncolytic adenovirus did not preclude the development 
of an antiadenoviral immune response. However, the 
presence of circulating antiadenoviral antibodies did not 
prevent the changes detected at the tumor masses. Therapy 
caused an increased infiltration and changes in the quality 
of immune cells per unit of tumor volume when compared 
to untreated mice. Tumor microenvironment showed a less 
protumoral and more inflammatory profile after treatment. 
We believe that the model described here will help us in 
optimizing this type of therapy by enabling the study of 
crucial events related to the immune responses affecting 
both the medicinal product and the tumor.
RESULTS
Mutant oncolytic adenovirus dlE102 replicates 
efficiently in adipose-derived murine MSC
To generate mCelyvir (murine version for human 
Celyvir used in the clinical setting [1, 3]), mesenchymal 
stem cell cultures were obtained from the white adipose 
tissue of mice, and were characterized by flow cytometry 
as described in Math & Methods. The oncolytic murine 
adenovirus MAV-1 dlE102 was previously developed 
by Dr. Katherine Spindler’s group [15]. Murine MSCs 
(mMSCs) were infected with mAd and viral replication 
was assessed by quantitative PCR (qRT-PCR). Detection 
of viral particles in the supernatants collected at days 2 
and 7 after infection increased over time (Supplementary 
Figure 1A, 1B, 1C). The cytopathic effect was followed by 
daily visual inspection. These findings are similar to those 
in the human system and allowed us to study the immune 
effects of murine Celyvir in an immunocompetent model 
of neuroblastoma.
Changes on adenovirus immunity upon systemic 
administration of murine Celyvir correlated with 
the presence of mAd particles in PB
Human Celyvir is administered weekly to patients 
so medicine biodistribution, virus replication and antivirus 
immune responses are important aspects of this therapy. 
Tumor bearing mice were treated during 3 weeks with 
mCelyvir (n=5) or naked virus (n=6) and PB samples were 
recovered before and one / two days after each treatment 
aiming at assessing the systemic immune response 
against the oncolytic virus. A scheme of experimental 
procedure is represented in Figure 1A. The anti-MAV 
neutralizing antibodies kinetic in serum showed that all 
treated mice had a positive titer of specific anti-adenovirus 
antibody while none of the untreated one did (Figure 1B). 
Interestingly, antibody levels were not detected until the 
third dose of either naked mAd or mCelyvir, being higher 
for the former compared with mCelyvir. Therefore, a 
systemic humoral immune response against the oncolytic 
virus followed the repeated administration of mCelyvir.
We also analyzed the presence of mAd virus in 
PB samples from mice treated with either naked virus or 
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mCelyvir. Samples from the first week were all negative. 
mAd genomic sequences were detectable in samples 
from the second week of treatment. We observed that 
particles of mAd decreased in both groups from the third 
week on, being only detectable in mCelyvir condition. 
Thus, circulating viral particles dropped when the titers 
of neutralizing anti-MAV1 antibodies raised (Figure 1C).
Anatomical distribution of systemically 
administered oncolytic adenovirus delivered in 
carrier mesenchymal stem cells
We assessed the biodistribution of the oncolytic 
adenovirus after repeated intravenous infusions. The 
mice of the experiment explained previously were 
exsanguinated and sacrificed one week after the fourth 
intravenous dose of either naked mAd or mCelyvir. 
Several organs and the tumor masses were procured. 
The administration of the oncolytic adenovirus in carrier 
cells resulted in higher accumulation of the virus in the 
tumor masses (p=0.08) and lungs (p=0.09), compared to 
the infusions of naked viruses. Although differences are 
not statically significant, there exists a tendency towards 
increased viral particles accumulation when using 
mCelyvir compared to naked viruses. No differences were 
found in spleens, livers and kidneys. The spleens and the 
lungs were the organs in which the highest amount of virus 
was detected (Figure 2).
Changes on local tumor immunity upon 
systemic administration of murine Celyvir in a 
spontaneous model of neuroblastoma
We next studied the local effects of IV administration 
of mCelyvir in tumor growth, intratumoral immune cell 
infiltration and expression of tumor microenvironment 
molecules, using the TH-MYCN transgenic mouse 
model (spontaneous model) as explained in Materials and 
Methods. The frequency of tumors was not significantly 
different among treated and untreated groups (5 out of 19 
vs. 6 out of 15, untreated vs. treated, p>0.1), similar to 
what it has been reported for this model [16]. Considering 
only the animals with macroscopic tumors, we found high 
variability on tumor volumes (Figure 3A, Supplementary 
Figure 2). Tumors were recovered and carefully minced. 
Cells were counted and fresh cell suspensions were labeled 
with specific flow cytometry antibodies in order to analyze 
tumor infiltrating immune cell populations. Complete 
Figure 1: Kinetic of circulating anti-adenovirus antibodies and viral particles following repeated infusions of 
mCelyvir. (A) Schematic representation of the experimental procedure. (B) MAV-1 relative quantitation of serum anti-adenovirus 
antibody levels of mice treated with mCelyvir or naked mAd. (C) qRT-PCR amplification of MAV-1 specific sequence from peripheral 
blood samples of the same mice.
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flow cytometry strategy is summarized in Supplementary 
Figure 3. We normalized the number of immune cells per 
milliliter of tumor to allow for comparisons. Even though 
no significant differences were found, tumors from treated 
mice showed a trend towards higher immune infiltration 
compared to untreated ones (Figure 3B). This difference 
was related to a higher infiltration of lymphocytes of the 
adaptive immune system, T- and B-lymphocytes (CD45+ 
CD3+ and CD45+ B220+, respectively), while myeloid 
(CD45+, CD11b+) and dendritic cell (CD45+, CD11c+) 
infiltration tended to be higher among untreated mice. 
All subsets of myeloid (MDSC-granulocytic, MDSC-
monocytic, M1-TAM, M2-TAM) and DC (plasmacytoid 
and conventional) showed higher numbers per mL in 
the control group. On the other hand, systemic therapy 
with mCelyvir resulted in non-significant increased 
mean values of CD8 and CD4 T lymphocytes per tumor 
volume, expressing markers of recent and sustained T cell 
activation (OX40 among CD8, PD1 and LAG3 among 
both CD4 and CD8, and TIM3 among CD4). CD4 and 
CD8 T lymphocytes expressing PD1 were enriched 150 
and 33 times respectively, relative to untreated mice 
(Supplementary Table 2). At the same time, we did not 
find differences in the percentages of these leukocyte 
subsets in peripheral blood. (Supplementary Figure 4).
We also quantified the expression levels of several 
genes related with immune function as mean of assessing 
the TME status and changes related with therapy. We 
found that treated mice expressed significant lower levels 
of genes associated to a protumoral TME (Arg1, Arg2, 
Foxp3, Il-10, Tgfβ, Vegf, Nos2) and higher (but non-
significantly) levels of genes associated to a sustained 
lymphocyte activation (CD80 and CD86, both ligands 
of CTLA-4) and a more inflammatory environment 
(chemokines CCL2 and CXCL10) (Figure 3C).
Changes on local tumor immunity upon systemic 
administration of murine Celyvir in an induced 
model of neuroblastoma
The fact that a significant number of spontaneous 
TH-MYCN animals did not develop tumor during the 
experimental period, and among those that did, the time 
of tumor initiation may not be homogeneous, contributed 
to the high variability found in the previous experiments. 
Therefore, the impact of therapy may not be comparable 
among groups. As alternative, we used an induced tumor 
model similar to that used for studying the systemic 
response and biodistribution experiments. In this model 
tumor cells are orthotopically implanted in the suprarenal 
area of wild type mice and therapy is given at the same 
time from tumor initiation.
Mice were treated and processed as explained 
before. All the animals showed macroscopic tumors in the 
area where cells were implanted. We found that tumors 
from treated mice (n=6) were significantly smaller than 
those of untreated controls (n=7) (Figure 4A, p=0.045, and 
Supplementary Figure 5). We also analyzed intratumoral 
immune populations by flow cytometry. We normalized 
the number of immune cells per milliliter of tumor to 
allow for comparisons. Tumors from treated mice had 
significantly higher immune infiltration compared to 
untreated ones, and this difference affected to all major 
leukocyte subpopulations (Figure 4B). Systemic therapy 
with mCelyvir resulted in increased numbers of CD4 
T lymphocytes, expressing markers of recent (OX40, 
4-1BB) and sustained T cell activation (PD1, LAG3 and 
TIM3) compared to untreated mice. The same was found 
for CD8, except for the expression of OX40, which was 
higher among control mice. CD4 and CD8 TILs expressing 
4-1BB were enriched 9 and 55-fold respectively, relative 
to untreated mice (Supplementary Table 2). Subsets of 
Figure 2: Differential biodistribution of MAV-1 in organs. qRT-PCR amplification of MAV-1 specific sequence from several 
organs and tumor recovered from mice treated with either naked MAV-1 or mCelyvir.
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MDSCs (granulocytic and monocytic), TAMs (TAM1 and 
TAM2) and DCs (plasmacytoid and conventional) were 
also higher in treated mice compared to control ones.
Finally, we performed qRT-PCR analysis to 
determine changes in expression of TME genes. The main 
changes found in gene expression levels affected Arg2 
(higher levels among treated mice) (Figure 4C).
DISCUSSION
Oncolytic virotherapy can be considered as a form 
of cancer immunotherapy [4], since the reported clinical 
benefits have been associated with antitumor immune 
phenomena initiated by infection and oncolysis. The role 
of the immune system during treatment with oncolytic 
viruses has two different facets, with a direct impact 
on the results of the therapy. On the one hand, antiviral 
immunity may be an important potential limitation. It 
has been described that natural killer (NK) cells interfere 
with the action of oncolytic viruses, decreasing and even 
eliminating their efficacy [17]. It is also known that 
adaptive immunity has developed many mechanisms to 
destroy viral infections [18]. On the other hand, oncolysis 
causes the death of tumor cells with the possible release of 
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tumor-associated antigens. These antigens, together with 
the danger signals [19] associated with viral infection, 
can stimulate an antitumor immune response [20] that 
increases the clinical effect in a very significant way.
The fact that MSCs are used for the production 
of Celyvir has very important implications in the 
development of immune responses that occur in these 
patients, which makes them different from those uses of 
virotherapy without MSCs. The effects that MSCs have 
on antigen-presenting cells (APCs, including DCs) and 
immune effector cells are well known [7–14]. It has also 
been reported that MSCs in the autologous context and in 
animal models can function as APCs [21, 22]. Therefore, 
the MSCs of Celyvir could exert an immunomodulatory 
role, participate in the presentation of antigens, or in both 
processes. In principle, MSCs infected with adenoviral 
vectors have not shown great changes in their phenotypic 
or functional characteristics [23]. From the point of 
view of the clinical practice with Celyvir, the MSCs 
could diminish the antiadenoviral response, due to its 
immunomodulatory role, facilitating and thus increasing 
the oncolytic action of the virus. In addition, the use of 
repeated administrations of an adenovirus (the regimen 
of treatment with Celyvir consists of weekly doses) could 
contribute to the depletion of the antiadenoviral immune 
response, comparable to that described in patients with 
other viral infections [24].
We present here a model that allows the study of 
many important aspects related to the Celyvir strategy 
we are developing in children with cancer. The TH-
MYCN mouse recapitulates the main genetic and clinical 
characteristics of NB with amplified MYCN, and has 
been used over the last 20 years in many studies of basic 
biology and preclinical research [25]. One aspect that has 
not been intensively studied in this model is the profile of 
infiltrating immune cells of the tumors, both at baseline 
and after the administration of treatments. This point is 
very important in the case of immunotherapies. In the TH-
MYCN mouse tumors develop in an immunocompetent 
host, with the appropriate tissue microenvironment, 
reproducing the conditions that allow the interaction of 
the immune system with the developing tumor.
We have treated these mice with a therapeutic 
regime similar to that we use in patients, i.e., an oncolytic 
adenovirus carried in MSCs, administered repeatedly 
through systemic infusions. MAV-1 is a murine oncolytic 
adenovirus comparable to ICOVIR-5 [1]: MAV-1 and 
ICOVIR-5 have genetic modifications that allow them to 
replicate preferentially in cells in which retinoblastoma 
(Rb) pathway is deregulated [15], a common feature of 
advanced human cancers (including neuroblastoma, NB) 
but not in healthy cells; MAV-1 and ICOVIR-5 are also 
able to replicate in MSCs, although at significant lower 
levels compared to replication in tumor cell lines [1] 
(Supplementary Figure 1A, 1B, 1C). We confirm an 
excellent safety profile for this therapy in mice, with no 
adverse effect or discomfort in the recipients (as happens 
in human patients [1–3]). Compared to naked virus, the 
repeated administration of mCelyvir resulted in relative 
accumulation of the oncolytic virus in organs such as 
spleen and lung, likely due to the sifting effect of these 
organs for the infused cells. Interestingly, mCelyvir also 
resulted in higher amount of virus in the tumor masses 
compared to the infusion of naked viral particles, 
underscoring that the carrier cells outcompeted the direct 
administration in oncolytic virotherapy. These results 
would indicate that Celyvir could efficiently target tumors 
metastasizing into the lungs, such as pediatric sarcomas or 
some adult carcinomas. The protection that MSCs could 
provide to the oncolytic adenovirus did not preclude the 
development of an antiadenoviral immune response, as 
manifested by our results not only in murine models but 
also in our experience in human patients [2]. However, the 
presence of circulating antiadenoviral antibodies did not 
prevent the changes detected at the tumor masses.
Less than half of the TH-MYCN mice developed 
a tumor during the time we did the experimental work, 
as it has been previously reported [16]. In addition, 
Figure 3: Effects of systemically administered mCelyvir in tumors in a spontaneous model of NB. (A) Tumor volumes 
recovered after four weekly treatments of intravenous mCelyvir and untreated controls. (B) Infiltrating immune cells per milliliter of tumor 
in both groups of animals. (C) Expression levels of immune-related genes of tumor microenvironment analyzed by qRT-PCR. Results were 
normalized to untreated controls (normalized value = 1). Statistics differences are represented by * (p < 0.05) or ** (p < 0.01).
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the time of tumor initiation is not homogeneous in this 
spontaneous model. Most mice develop tumors between 
weeks 6 and 9 of life, predominantly in the paraspinal 
region of these mice, and can be palpated only when 
they are large enough, which makes very difficult to 
know when a tumor is initiating on these mice. Also, no 
image system was available to follow up the development 
of these tumors and therefore choose the best moment 
to start treatment. All these facts pose limitations and 
account for a high variability of results when therapies are 
administered at the same starting time-point. Therefore, 
in addition to the spontaneous model we used an induced 
one, in which tumor cells are orthotopically implanted in 
the suprarenal area of 129/SvJ wild type mice [26–28]. 
In the latter, conditions such as frequency of tumors 
and time of tumor initiation are similar among animals 
in treated and control groups. Using any of the models 
we found that the systemic administration of mCelyvir 
resulted in local changes in the tumor masses related to 
their immune landscape. Since we did not find major 
changes in circulating leukocytes (Supplementary Figure 
4), the scenario at the tumor represents a localized rather 
than generalized effect. Therapy caused an increased 
infiltration of immune cells per unit of tumor volume 
when compared to untreated mice. The recruitment of 
immune cells has been already reported when oncolytic 
viruses were administered directly into the tumor masses 
[29, 30] and our results show that the same happens when 
carrier cells systemically deliver the virus. We could also 
prove the presence of oncolytic virus in the tumor masses 
upon sacrifice.
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Therapy also caused changes in the quality of 
immune cell infiltrates. Increased B and T lymphoid 
infiltration was independent of the type of model analyzed, 
while myeloid and DC subsets were affected mainly in 
the induced model. Others have reported that intratumoral 
administrations of oncolytic viruses in mice [29, 31] 
induced inflammatory responses with activation of CD4 
and CD8 T lymphocyte infiltration in treated lesions. We 
also found that infiltrating CD4 and CD8 lymphocytes 
showed changes in markers of T cell activation and 
exhaustion upon repeated mCelyvir administration [32], 
suggesting continued activity of the tumor infiltrating 
T lymphocytes (TILs). TILs expressing activation 
markers were more enriched (relative to untreated mice) 
in the induced model, both CD4 and CD8, while the 
spontaneous model showed enrichment of CD4 and CD8 
expressing exhaustion markers. Although we did not test 
the specificity of TILs activity in this work (antitumoral / 
antiadenoviral / non-specific), the immunophenotypic 
differences suggest a more active and less exhausted TIL 
repertoire in the induced model after mCelyvir therapy, 
which might explain the better antitumoral effect seen in 
terms of tumor volume.
We also analyzed changes related to the tumor 
microenvironment, specifically of molecules with a known 
role in the balance pro and antitumoral that modulates 
tumor growth. Systemic administration of mCelyvir was 
followed by changes in the TME, more remarkable in the 
spontaneous model than the induced one. After treatment, 
TME showed a less pro-tumoral and more inflammatory 
profile, a scenario that contributes to create a more pro-
immune local situation for an antitumor immune response, 
as has been previously described [33, 34]. Today it is 
well accepted the immunomodulatory role associated 
to oncolytic virotherapy through several secondary 
mechanisms derived from the tumor cell infection 
itself [6]. In our experience, TME changed towards a 
more inflamed environment, evidenced by the increase 
of cytokines like CXCL10 and CCL2 [35, 36], and the 
decrease of immunosuppressive molecules (like FoxP3 
and Nos2), and molecules that promote tumor growth and 
invasiveness (like IL10 and TGFβ) [37–39]. Therefore, 
oncolytic virotherapy with Celyvir could have not only a 
lytic effect in tumor cells, but could also immunomodulate 
the TME so other therapies can be administered with a 
higher chance of achieving a clinical response.
We are using the Celyvir strategy to treat kids with 
metastatic tumors [1–3]. We have found changes in the 
immune landscape of primary tumors of patients receiving 
Celyvir, similar to those described in this paper [27]. We 
found differences in immune cell infiltration and gene 
expression levels when comparing the spontaneous versus 
induced model, considering only non-treated mice. There 
were higher levels of immune infiltration and levels of 
gene expression (pro- and anti-tumoral genes) in the non-
treated mice of the spontaneous model (Supplementary 
figure 6A, 6B). These differences may likely be due 
to the extended time and more physiological process 
for tumor and TME development in the spontaneous 
model, and the higher numbers of tumor initiating cells 
in the induced one. The impact of mCelyvir therapy in 
each scenario was different, changes in infiltration and 
TME more pronounced in the spontaneous model and 
tumor volume in the induced one. These differences in 
the response to mCelyvir may be related to the different 
doses used in each model. Nevertheless, even though these 
Figure 4: Effects of systemically administered mCelyvir in tumors in an induced model of NB. (A) Tumor volumes from TH-
MYCN recovered after two weekly treatments of intravenous mCelyvir and untreated controls. (B) Infiltrating immune cells per milliliter 
of tumor in both groups of animals. (C) Expression levels of immune-related genes of tumor microenvironment analyzed by qRT-PCR. 
Results were normalized to untreated controls (normalized value = 1). Statistics differences are represented by * (p < 0.05) or ** (p < 0.01).
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two models are not completely identical, and taking into 
account differences in the murine and human oncolytic 
adenoviruses, we believe that the models described here 
will help us in optimizing this type of therapy by enabling 
the study of crucial events related to the immune responses 
affecting both the medicine and the tumor.
MATERIALS AND METHODS
Mice
TH-MYCN- 129X1/SvJ transgenic mice [40] were 
used for spontaneous tumor treatment experiments. Wild 
type mice were also used for mouse NB tumor cell line 
transplant experiments. All mice were bred, maintained 
and used following guidelines issued by the European 
and Spanish legislations for laboratory animal care. 
All experiments involving animals were approved by 
the OEBA (Organ for Evaluating Animal Wellbeing) 
at CIEMAT and Madrid Regional Department of 
Environment, with reference PROEX 186/15. Transgenic 
mice were identified as previously described [41] using 
N008 (5'-TGGAAAGCTTCTTATTGGTAGAAACAA-3') 
and N009 (5'-AGGGATCCTTTCCGCCCCGTTCGTTTT
AA-3') for human MYCN gene detection.
Cell culture and virus production
WT 129/SvJ mice derived mesenchymal stem cells 
(mMSC) were obtained from adipose tissue enzymatically 
digested with 1 mg/mL of collagenase B (Roche; Catalog 
#11088815001) during 2 hours at 37ºC in constant 
shaking. Mononuclear cells were washed twice with PBS 
and pelleted by centrifugation at 1500 rpm for 5 minutes. 
Cells were seeded at 100.00 cells / cm2 with murine 
MesenCult Expansion Kit (STEMCELL Technologies; 
Catalog #05513) until passage 3. From then on mMSC 
were maintained with DMEM with Glutamax (Gibco) 
supplemented with 10% FBS (HyClone, GE Healthcare 
Life Sciences) and 1% penicillin / streptomycin (10.000 
U/mL, Gibco; Catalog #15140122). Murine MSC were 
characterized by flow cytometry with specific antibodies.
Non-adherent spheres derived from a TH-MYCN 
tumor mass (36769 cell line) were generated in Dr. Louis 
Chesler’s laboratory. They were maintained using DMEM/
F12 (Gibco; Catalog #10565018) supplemented with 1X 
B-27 without vitamin A (Gibco; Catalog #12587010), 
20 ng/mL of murine EGF and 40 ng/mL of murine FGF 
(R&D Systems, Minneapolis, MN). Spheres were passed 
when confluents, and seeded again at 1/6 of its initial 
concentration.
The 37.1 cell line was used for MAV-1 dlE102 
virus production. The oncolytic murine adenovirus 
MAV-1 dlE102 (mAd) was previously developed by Dr. 
Katherine Spindler’s group [15]. Similar to ICOVIR-5 
[1], MAV-1 has genetic modifications that allows it to 
replicate preferably in cells in which retinoblastoma (Rb) 
pathway is deregulated [15]. First virus aliquot was kindly 
provided by Dr. Spindler. Successive virus stocks for our 
experiments were produced in our lab using 37.1 cells as 
previously described by Spindler group. The cells were 
maintained with DMEM (4.5 g/L glucose, Gibco; Catalog 
#11965092) supplemented containing 5% FBS (Hyclone, 
GE Healthcare Life Sciences) and G418 (200μg/mL, 
Sigma; Catalog #G8168-10ML). For virus propagation, 
cells were passaged one time in absence of G418, and 10-
5M dexamethasone was added 5-24 hours prior infection 
to induce E1A expression [15]. Viral physical titer from 
supernatants was determined by spectrophotometry using 
NanoDrop 1000 (Thermo Fisher Scientific, Waltham, MA 
USA) and aliquoted and stored at -80ºC until use.
Preparation of murine Celyvir
For murine Celyvir (mCelyvir) preparation, 
mMSC were used between passages 5 and 7 for every 
experiment. Cells were trypsinized (TripLE Express, 
Life Technologies; Catalog #12604013) and counted 
with trypan blue. Viable mMSC were infected at MOI 
200 with MAV-1 dlE102 during 90 minutes at 37º C in 
constant shaking. After that, cells were washed to remove 
virus excess and resuspended for intravenously (IV) 
administration in mice (100.000 infected cells in 150 μL 
of non-supplemented DMEM).
Tumor mice model and mCelyvir treatment
We either used the TH-MYCN transgenic mouse 
model (spontaneous) or implanted 3 x 105 TH-MYCN 
cells on the suprarenal region of 129/SvJ mice (genetic 
background of the TH-MYCN transgenic mouse, induced 
model).
All treatments were administered intravenously, 
either mCelyvir or naked adenovirus.
In the spontaneous model, 8 weeks old TH-MYCN 
mice were treated intravenously with mCelyvir during 
4 weeks while control group remained untreated. Both 
groups of mice were sacrificed two days after the 4th 
treatment and peripheral blood and tumor mass were 
obtained.
For the induced tumor model, 3 x 105 cells from 
a single cell suspension of the 36769 cell line were 
inoculated into the left adrenal gland of 129/SvJ-WT mice 
by surgery. Mice were left to recover for 2 weeks and 
then received 2 weekly doses of mCelyvir or remained 
untreated. Mice were sacrificed two days after the second 
treatment and peripheral blood and tumor mass were 
analyzed.
Tumor volume was calculated with the formula 
(3.14/3)×(a/2)2×(b/2). A tumor piece was conserved at 
-80ºC for qRT-PCR analysis. The rest of the tumoral mass 
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and the peripheral blood were processed freshly for flow 
cytometry analysis.
Biodistribution and viral replication studies
Mice with implanted tumors were treated 
intravenously during 3 weeks with mCelyvir or naked 
adenovirus once per week. The amount of naked mAd 
used was equivalent to that used in Celyvir preparation. 
After the last treatment, mice were sacrificed and bone 
marrow, spleen, lung, liver, kidney, tumor mass and 
peripheral blood (PB) were extracted to further analyze 
the presence of viral DNA in the different tissues.
For detection of mAdv presence on tumors, 
conventional PCR reaction was performed with 30 ng of 
genomic DNA using GoTaq® DNA Polymerase (Promega, 
Madison USA; Catalog #M7822) and specific MAV-1 
forward (5’-GGCCAACACTACCGACACTT-3’) and 
MAV-1 reverse (5’-TTTTGTCCTGTGGCATTTGA-3’) 
primers. Conventional PCR reaction consisted in an 
initial denaturation at 95ºC for 10 minutes followed by 40 
cycles at 95ºC for 15 seconds and 65ºC during 1 minute, 
as previously described [42].
To study the kinetics of viral particles in peripheral 
blood, treated mice were bleed just before each treatment 
and also one-two days after. qRT-PCR was performed 
using hexon (MAV-1) and ApoB (as genomic control) 
primers. The same qRT-PCR procedure was used to 
quantify adenovirus in distinct organs (bone marrow, 
spleen, lung, liver, kidney). The reactions were run in a 
7500 Real-Time PCR System (Applied Biosystems™, 
California USA) and results were analyzed using 7500 
Real-Time PCR software (Applied Biosystems™, 
California USA). Standard curves of genomic DNA and 
MAV-1 DNA were used for quantitation purposes.
Flow cytometry analysis
To confirm the phenotype of mMSC cells were 
stained with specific antibodies during 30 min at 4 
degrees. MSC were positive for CD29, CD44, and Sca-
1 and negative for CD45, CD11b, and CD14 (data not 
shown).
To analyze immune infiltrated cells, tumor mass 
was carefully washed with HBSS 1X and mechanically 
processed prior enzymatic digestion with 1 mg/mL of 
collagenase D (Roche; Catalog #11088858001). Tumor 
cell suspension was counted by trypan blue and 5 x 105 
alive cells were labelled with specific antibodies during 
30 min at 4 degrees. Red blood cells were lysed using 
QuickLysis (Cytognos; Catalog #CYT-QL-1) for 20 min in 
darkness. Used antibodies are indicated in supplementary 
information (Supplementary Table 1). Samples were 
acquired in a FacsCanto II (BD, San Jose, CA) cytometer 
and analyzed using FacsDiva software.
RNA extraction and qRT-PCR analysis
To analyze gene expression of different stroma 
genes, chemokines and immune-related molecules, 30 μg 
of each tumor piece conserved at -80ºC were mechanically 
disrupted and RNA extraction was performed with RNeasy 
Mini kit (Qiagen; Catalog #74106). RNA concentration was 
determined by NanoDrop 1000. For cDNA synthesis, 1 μg 
of RNA was retrotranscribed using SuperScript™ VILO™ 
cDNA Synthesis Kit (Invitrogen, Catalog #11754050). 
For qRT-PCR analysis, specific murine TaqMan assays 
(Applied Biosystems™, California USA) were used: 
Gapdh (Mm99999915_g1), Arg1 (Mm00475988_m1), 
Arg2 (Mm00477592_m1), Ccl2 (Mm00441242_m1), 
Cd80 (Mm00711660_m1), Cd86 (Mm00444543_m1), 
Cxcl10 (Mm00445235_m1), FoxP3 (Mm00475162_m1), 
Ifnγ (Mm01168134_m1), Il-10 (Mm00439614_m1), Pdl1 
(Mm00452054_m1), Tgfβ (Mm01178820_m1), Vegf 
(Mm01281449_m1) and Nos2 (Mm00440502_m1).
qRT-PCR reaction was performed in a 7500 Real-
Time PCR System (Applied Biosystems™, California 
USA) and results were analyzed using 7500 Real-Time 
PCR software (Applied Biosystems™, California USA). 
A relative quantification was used (DDCt method) using 
non-treated groups of mice as reference.
Serological studies
Fresh blood collected from spontaneous model TH-
MYCN mice at the moment of sacrifice was tested for 
detection of specific MAV-1 antibodies in serum using 
Mouse Adenovirus (FL/K87) ELISA Kit (Dynamimed, 
Madrid Spain). Experiment was performed following 
manufacturer’s instructions. Briefly, peripheral blood 
samples were collected from animals and serum was 
obtained by centrifugation and diluted 50 times in order 
to proceed with ELISA. Samples were incubated in the 
plate as well as proper positive and negative controls at 
37ºC during 45 minutes. Wells were carefully washed five 
times before adding peroxidase conjugate and incubate 
again at 37ºC during 45 minutes. After last five washes, 
peroxidase substrate was added and plate was incubated 
for 30 minutes prior to read the absorbance at 495 nm.
Statistics
All statistical analyses were performed using Stata/
IC 11.0 (StataCorp LP, College Station, TX, http://www.
stata.com/). The nonparametric Wilcoxon rank-sum 
test was used to compare quantitative variables. Results 
were considered statistically significant with p<0.05. All 
graphics present the mean ± SEM.
Graphics
All graphics presented in this work have been created 
using GraphPad Prism 7 (https://www.graphpad.com/).
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